1207 - Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies

Page last updated: 11 October 2016

Application Detail



Description of Medical Service

BRAF V600 mutation testing for locally advanced unresectable stage III or IV melanoma to determine eligibility for access to dabrafenib (co-dependent technology).

Description of Medical Condition

Melanoma in its advanced form has a poor prognosis. It is increasing in incidence in Australia and globally, and occurs when mutations accumulate in the melanocytes of the skin, mainly as a result of exposure to ultra-violet radiation from sunlight. When mutations accumulate they can eventually deregulate growth and cell cycle control genes, and to lead to tumour formation through proliferation and metastasis of cells.

Reason for Application


Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation

12-13 April 2012
Final Decision Analytic Protocol (PDF 2745 KB)
Final Decision Analytic Protocol (DAP) (Word 1022 KB)

Assessment Report


Public Summary Document

Public Summary Document - April 2013 (PDF 85 KB)
Public Summary Document - April 2013 (Word 678 KB)

Public Summary Document - August 2013 (PDF 80 KB)
Public Summary Document - August 2013 (Word 78 KB)

Predicted versus Actual

Public Summary Document - November 2016 (Word 144 KB)
Public Summary Document - November 2016 (PDF 786 KB)

Meetings for this Application


1 to 2 December 2012
12 to 13 April 2012


13 to 14 June 2013


5 April 2013
1 August 2013
24-25 November 2016